October 30, 2013
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
NICE recommends reimbursement for Jetrea in England, Wales
The final ruling recommended reimbursing Jetrea (ocriplasmin, ThromboGenics/Alcon) for patients with vitreomacular traction and full-thickness macular holes up to 400 µm in diameter in the absence of epiretinal membrane.
The ruling also recommended reimbursing Jetrea when used to treat patients with metamorphopsia, an early symptom of vitreomacular traction.
Alcon, ThromboGenics’ marketing partner, launched Jetrea in the U.K. in April. Jetrea was approved in the European Union in March.